
Couple bought an abandoned house in Vancouver for a $1.5 million, has spent over $250,000 renovating so far—take a look inside
Though the listing shared photos of just the exterior and described the house as a "tear-down," the 28-year-old program manager tells CNBC Make It that what stood out the most was that the property was priced much lower than those in the surrounding area.
Plus, it had a view of the water, and wasn't your standard modern home.
Jenna Phipps, a 29-year-old content creator, says she fell in love, but wanted to get out to see the house in person as soon as possible.
"There was a reason they didn't show photos of the inside," she says.
The Vancouver property is a 2,757-square-foot single-family home, built in 1961. It had three bedrooms, 2.5 bathrooms, a pool, and sits on 0.30 acres.
The house was so dilapidated that the realtor asked the couple to sign a waiver before going inside.
"You can really see this property had not been cared for at all," Volkov says. "There was a really musty smell with the old furniture and old things in there."
Still, the couple were able to find some beauty in the space. "The architecture showed through all of that. You could see what it was in its former days," Volkov says.
"Even with it falling apart, it was still really pretty."
The couple made an offer of $2.1 million CAD — $1,525,923 USD at the time — and it was accepted. They closed on the property in January 2024.
"People were very shocked at how we were able to get that price, especially in that area," Phipps says. "We kind of bought the worst thing in a great neighborhood."
The median list price of homes in Vancouver was $1,578,540 in March 2024, according to Houseful, a subsidiary of the Royal Bank of Canada.
The property's rundown condition meant Volkov and Phipps were unable to obtain a traditional mortgage and had to apply for a private two-year loan instead. They split the 20% down payment evenly.
When Phipps and Volkov took possession of the house, it had been empty for four years and was deteriorating. The seller lived several hours away and would rarely visit.
"It was in a state that probably no one should have lived there," Phipps says.
When the couple closed on the house in 2024, their first order of business was clearing it out.
They had hopes of preserving some of the structure's original features, like the wood paneling, but ended up having to take the house down to the studs. There was extensive water damage and mold that had grown over the years that the house was abandoned.
That summer, Volkov and Phipps worked to get rid of the roof, windows, ducting, and electrical. In October, the couple hired contractors to help rebuild the roof and frame of the house.
"We're pretty much at the stage where it feels like a real home," she says.
The couple did most of the work on their new home themselves. They would work six days at the house from 7:30 a.m. until 5:30 p.m. while documenting the journey for Phipps' YouTube channel. On Sundays, they would spend most of the day working on content creation.
"We work really hard because we want to keep showing videos and showing a process to everyone," Phipps says. "Having that support from so many people cheering us on, I think that was great accountability, too."
Phipps says the renovation process has been hard, but even just getting windows installed helped them picture what life will be like once they can finally move in.
"For a while over the winter, it was mentally challenging and now we're finally at that exciting stage where we actually see it. I think we're finally enjoying all this hard work we put in."
The couple will pay homage to the original space by having some of the wood paneling details restored.
"We look at the home and we're like 'Wow, this is beautiful.' We have the exact same home but just a new form. We pretty much recreated it," Phipps says.
Volkov and Phipps are planning to replicate some of the original furniture that came with the sale of the house, but that they had to get rid of. They also modified the floor plan slightly to make the house a four-bedroom, two-and-a-half-bathroom, and kept the exterior the same.
The couple had an initial budget of $220,792 USD with a max limit of $294,389. They've since gone over budget and had to readjust.
Phipps says they've already spent over $257,590 and is hoping to stay at or under $441,583 going forward.
"We chose to go over budget because we're going the extra mile to have a better quality home," she says. "It's obviously not the greatest thing to see higher bills come in, but we're so invested in this project. It's an investment and that's how we're looking at it."
The couple plans to transition to a traditional mortgage next January.
"We're hoping that it will be at that livable standard so we can get it reevaluated with a traditional bank," Phipps says. "We would love to move in by the end of the year, so we're working very hard to try to still get to that goal."
Phipps knew from the very beginning that once it became theirs's, she didn't want to ever sell the house. Now that they've put in a year's worth of work, she's even more adamant about that.
"I don't think there would ever be a price tag out there that I would be able to sell it for or at least not anytime soon," she says. "I really want to enjoy the home."
74

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Output to Register an AAGR of 3.6% During 2026-2029, Supported by Investments in Hydrogen, Transport and Water Infrastructure Projects
Uruguay's construction industry rebounds, projected to grow 3.7% in 2025 after a 0.8% dip in 2024, bolstered by robust regulations and investments in water, transport, and solar energy. The sector is set for 3.6% average annual growth through 2029, fueled by hydrogen initiatives and a strong USD 8.9 billion project pipeline. Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "Uruguay Construction Market Size, Trends, and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis to 2029 (H1 2025)" report has been added to a marginal decline of 0.8% in real terms in 2024, Uruguay's construction industry to expand by 3.7% in 2025; a feat underscored by robust institutions, developed regulatory frameworks, and labor intensive construction practices. Growth will be supported by investment in water and transportation infrastructure projects, increased tourism activity, and governments plan to add 200MW of solar energy and achieve 400GWh of electricity production annually by over the remainder of the forecast period, the construction industry is expected to register an annual average growth rate of 3.6% in real terms, between 2026 and 2029, supported by investments in hydrogen industries, coupled with investment in transport and water infrastructure projects. Growth over the forecast period is also supported by Uruguay's green hydrogen and derivatives roadmap; under which, the government aim to attract UYU746.4 billion ($18 billion) investment by 2040. According to the analyst project pipeline, Uruguay had a total of UYU369.1 billion ($8.9 billion) of construction projects in the pipeline as of May 2025. Major projects include Green Hydrogen and Power Plant Development in Paysandu, expected to start in Q3 2025 and end by Q4 2027 with an investment of UYU165.9 billion ($4 billion); a Modern City Development in Colonia, started in Q2 2025 and expected to end by Q4 2033 with an investment of UYU82.9 billion ($2 billion); and the Canelones Data Center Development in Canelones, started in Q3 2024 and expected to end by Q4 2026, with an investment of UYU35.2 billion ($850 million). Furthermore, in 2024, the government announced an investment of UYU20.7 billion ($500 million) for the development of sanitation projects nationwide by 2028Scope Historical (2020-2024) and forecast (2025-2029) valuations of the construction industry in Uruguay, featuring details of key growth drivers. Segmentation by sector (commercial, industrial, infrastructure, energy and utilities, institutional and residential) and by sub-sector Analysis of the mega-project pipeline, including breakdowns by development stage across all sectors, and projected spending on projects in the existing pipeline. Listings of major projects, in addition to details of leading contractors and consultants Reasons to Buy Identify and evaluate market opportunities using our standardized valuation and forecasting methodologies Assess market growth potential at a micro-level with over 600 time-series data forecasts Understand the latest industry and market trends Formulate and validate business strategies using the analyst's critical and actionable insight Assess business risks, including cost, regulatory and competitive pressures Evaluate competitive risk and success factors Key Topics Covered: 1 Executive Summary2 Construction Industry: At-a-Glance3 Latest news and developments4 Project analytics5 Construction Market Data6 Risk Profile7 AppendixFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Hemostemix Closes $469,366 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of the issuance of 3,911,385 Common Shares at a price of CAD $0.12. As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a Related Party to the Company at the time of disclosure. The use of proceeds will be allocated to general working capital purposes, supporting the Company's continuing operational expenses and business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. All securities issued in connection with the Offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in ten peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Closing of a non brokered private placement, in furtherance of sales in Florida of VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
3 hours ago
- Business Upturn
Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market
Lupin Limited has announced the launch of its generic version of Ipratropium Bromide Nasal Solution in the United States. The product will be available in both 0.03% and 0.06% strengths and is a therapeutic equivalent to Boehringer Ingelheim's Atrovent® Nasal Spray. This launch marks Lupin's latest addition to its U.S. generic portfolio. The Ipratropium Bromide Nasal Solution 0.03% is used to provide symptomatic relief of rhinorrhea linked to both allergic and nonallergic perennial rhinitis in adults and children aged six and above. The 0.06% version targets rhinorrhea symptoms associated with the common cold or seasonal allergic rhinitis in adults and children aged five and older. According to IQVIA data for the 12 months ending May 2025, the reference drug Atrovent® recorded estimated annual U.S. sales of approximately USD 63 million. With this launch, Lupin aims to tap into the niche respiratory care segment while expanding access to affordable treatment options for patients in the U.S. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at